Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer
- PMID: 7577480
- PMCID: PMC2033922
- DOI: 10.1038/bjc.1995.498
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer
Abstract
Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
